Top Markets
Coin of the day
Mallinckrodt plc Mallinckrodt plc

Mallinckrodt plc

MNK
Rang în acțiuni #30225
Mallinckrodt plc operates as a global pharmaceutical company, engaged in the... Mallinckrodt plc operates as a global pharmaceutical company, engaged in the development, manufacturing, marketing, and distribution of specialized medical products and therapies. Its extensive reach covers the United States, Europe, the Middle East, Africa, and various other international markets. The firm's business operations are segmented into two core divisions: Specialty Brands and Specialty Generics. Under its Specialty Brands arm, Mallinckrodt offers a range of pharmaceuticals for autoimmune and rare diseases, spanning therapeutic areas such as neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology. The branded portfolio also encompasses immunotherapy solutions, critical care treatments for neonatal respiratory conditions, pain management drugs, cultured skin substitutes, and gastrointestinal remedies. Key branded products include Acthar Gel, a corticotropin injection prescribed for conditions like rheumatoid arthritis, infantile spasms, and multiple sclerosis; INOmax, a vasodilator used to enhance oxygenation and lessen the need for extracorporeal membrane oxygenation; the Therakos photopheresis platform for immunotherapy; Amitiza, a treatment for constipation; and StrataGraft, designed for adults with deep partial-thickness burns. In its development pipeline, Mallinckrodt is advancing Terlipressin for hepatorenal syndrome and SLN 501, a ribonucleic acid silencing therapeutic. Additionally, through its Specialty Generics segment, the company supplies specialized generic medications and active pharmaceutical ingredients (APIs). Mallinckrodt's branded offerings are marketed to a diverse array of healthcare professionals and institutions, including physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company has also forged a strategic collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference (RNAi) drug targets. Established in 1867, Mallinckrodt plc maintains its headquarters in Dublin, Ireland.
Preț acțiune
$0.1
Ultima sincronizare: 2023-09-19
Capitalizare de piață
$17.68M
Schimbare (1 zi)
-4.76%
Schimbare (1 an)
0.00%
Țară
IE
Tranzacționează Mallinckrodt plc (MNK)

Categorie

Istoricul randamentului dividendelor pentru Mallinckrodt plc (MNK)
Randamentul dividendelor (TTM) pentru Mallinckrodt plc (simbol acțiune: MNK) la data de 2026 este: 0
Randamentul mediu al dividendelor în ultimii 5 ani: 0.00%
Istoric al randamentului dividendelor pentru Mallinckrodt plc (MNK) între 2026 și 2026
Randamentul dividendelor la sfârșitul fiecărui an (TTM)
An Randamentul dividendelor Schimbă
Nu sunt suficiente date pentru perioada selectată.
Randamentele dividendelor (TTM) pentru companii similare sau concurente